Age-related macular degeneration

Patients with neovascular AMD are treated and monitored until the disease is stable and inactive. Adopt a personalised interval according to the drug posology. When the longest treatment interval has been reached for the drug in use, and the disease is judged to be inactive, monitoring without treatment may be considered. Monitoring is typically done using vision measurement and optical coherence tomography scanning at 4-8 week intervals for 1-2 years after the last injection. Treatment is re-initiated if disease recurs.

There is no clear evidence to recommend specific monitoring protocols for patients with Age-Related Eye Disease Study Group (AREDS) category 1-3 disease or geographic atrophy (dry) AMD.

Fundus photography and autofluoresence may be used to follow progression.

See Patient discussions.